Form 8-K - Current report:
SEC Accession No. 0001725160-25-000127
Filing Date
2025-06-18
Accepted
2025-06-18 16:09:28
Documents
13
Period of Report
2025-06-17
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K zntl-20250617.htm   iXBRL 8-K 41189
  Complete submission text file 0001725160-25-000127.txt   180462

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT zntl-20250617.xsd EX-101.SCH 2039
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT zntl-20250617_def.xml EX-101.DEF 5702
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT zntl-20250617_lab.xml EX-101.LAB 24316
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT zntl-20250617_pre.xml EX-101.PRE 17888
15 EXTRACTED XBRL INSTANCE DOCUMENT zntl-20250617_htm.xml XML 2835
Mailing Address 10275 SCIENCE CENTER DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 10275 SCIENCE CENTER DRIVE SUITE 200 SAN DIEGO CA 92121 (858) 263-4333
Zentalis Pharmaceuticals, Inc. (Filer) CIK: 0001725160 (see all company filings)

EIN.: 823607803 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39263 | Film No.: 251056994
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)